Drug Profile
Research programme: immuno-oncology therapeutics - Avvinity Therapeutics
Alternative Names: Alphamers - Avvinity TherapeuticsLatest Information Update: 28 Sep 2023
Price :
$50
*
At a glance
- Originator Avvinity Therapeutics
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Epidermal growth factor receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Leukaemia; Solid tumours
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for research development in Solid-tumours in United Kingdom
- 28 May 2020 No recent reports of development identified for research development in Leukaemia in United Kingdom (Parenteral)
- 19 Aug 2019 Early research in Leukemia in United Kingdom before August 2019 (Parenteral)